Lyra Therapeutics Announces Reverse Stock Split Decision

An announcement from Lyra Therapeutics ( (LYRA) ) is now available.

On May 14, 2025, Lyra Therapeutics held its Annual Meeting of Stockholders where key decisions were made, including the election of two Class II Directors and the approval of a reverse stock split. The reverse stock split, set at a ratio of 1-for-50, will become effective on May 27, 2025, with trading on a split-adjusted basis commencing on May 28, 2025. This strategic move is aimed at consolidating shares to potentially enhance the stock’s marketability and meet trading requirements.

The most recent analyst rating on (LYRA) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Lyra Therapeutics stock, see the LYRA Stock Forecast page.

Spark’s Take on LYRA Stock

According to Spark, TipRanks’ AI Analyst, LYRA is a Neutral.

Lyra Therapeutics faces significant financial and technical challenges, reflected in its low score. Persistent losses and negative cash flows highlight financial instability, while bearish technical indicators suggest continued downward pressure on the stock. The negative P/E ratio and lack of dividend yield further underscore the valuation concerns. Strategic adjustments are essential to improve the company’s financial position and investor appeal.

To see Spark’s full report on LYRA stock, click here.

More about Lyra Therapeutics

Lyra Therapeutics, Inc. operates in the biotechnology industry, focusing on developing therapies for ear, nose, and throat (ENT) diseases. The company is known for its innovative drug delivery platforms that target chronic rhinosinusitis and other ENT conditions.

Average Trading Volume: 3,218,864

Technical Sentiment Signal: Sell

Current Market Cap: $7.4M

Find detailed analytics on LYRA stock on TipRanks’ Stock Analysis page.